PXD030132 is an
original dataset announced via ProteomeXchange.
Dataset Summary
Title | Combination antiretroviral therapy and MCL1 inhibition mitigate HTLV-1 infection in vivo |
Description | We analysed HTLV-1 subtype-associated changes in the host proteome of infected CD4+ T cells from animals by quantitative label-free based proteomics analysis. |
HostingRepository | PRIDE |
AnnounceDate | 2025-07-11 |
AnnouncementXML | Submission_2025-07-11_08:03:52.148.xml |
DigitalObjectIdentifier | |
ReviewLevel | Peer-reviewed dataset |
DatasetOrigin | Original dataset |
RepositorySupport | Unsupported dataset by repository |
PrimarySubmitter | Laura Dagley |
SpeciesList | scientific name: HTLV-1 subtype A; NCBI TaxID: 402042; scientific name: Homo sapiens (Human); NCBI TaxID: 9606; |
ModificationList | monohydroxylated residue; iodoacetamide derivatized residue |
Instrument | timsTOF Pro |
Dataset History
Revision | Datetime | Status | ChangeLog Entry |
0 | 2021-12-02 07:44:37 | ID requested | |
⏵ 1 | 2025-07-11 08:03:52 | announced | |
Publication List
Keyword List
submitter keyword: label-free proteomics, BCL2,HTLV, MCL1 |
Contact List
Prof. Marc Pellegrini |
contact affiliation | Laboratory Head Walter and Eliza Hall Institute of Medical Research 1G Royal Parade, Parkville, AUS 3052 |
contact email | pellegrini@wehi.edu.au |
lab head | |
Laura Dagley |
contact affiliation | WEHI |
contact email | dagley.l@wehi.edu.au |
dataset submitter | |
Full Dataset Link List
Dataset FTP location
NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2025/07/PXD030132 |
PRIDE project URI |
Repository Record List
[ + ]
[ - ]
- PRIDE
- PXD030132
- Label: PRIDE project
- Name: Combination antiretroviral therapy and MCL1 inhibition mitigate HTLV-1 infection in vivo